GOLDENWELL BIOTECH, INC. (GWLL) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
581 BOSTON MILLS ROAD, SUITE 300 HUDSON, OH 44236 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 20 - Food And Kindred Products (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 53,231 | 45,996 | 213,556 | 248,569 | |||
| Cash and cash equivalents | 53,231 | 45,996 | 213,556 | 248,569 | |||
| Inventory, net of allowances, customer advances and progress billings | 174,825 | 176,058 | 198,671 | ||||
| Inventory | 174,825 | 176,058 | 198,671 | ||||
| Total current assets: | 228,056 | 222,054 | 412,227 | 248,569 | |||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 26,346 | 48,753 | |||||
| Total noncurrent assets: | 26,346 | 48,753 | |||||
| Other undisclosed assets | 1 | (1) | |||||
| TOTAL ASSETS: | 228,057 | 248,400 | 460,979 | 248,569 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 111,488 | ||||||
| Accounts payable | 111,488 | ||||||
| Other undisclosed current liabilities | 26,782 | 47,778 | |||||
| Total current liabilities: | 26,782 | 159,266 | |||||
| Noncurrent Liabilities | |||||||
| Other undisclosed noncurrent liabilities | 20,000 | ||||||
| Total noncurrent liabilities: | 20,000 | ||||||
| Other undisclosed liabilities | 143,334 | ||||||
| Total liabilities: | 143,334 | 46,782 | 159,266 | ||||
| Equity | |||||||
| Equity, attributable to parent, including: | 84,723 | 201,618 | 301,713 | 248,569 | |||
| Common stock | 9,900 | 9,900 | 9,600 | 9,150 | |||
| Common stock, value, subscriptions | 78,300 | ||||||
| Additional paid in capital | 1,302,504 | 1,302,504 | 417,804 | 326,354 | |||
| Accumulated deficit | (1,227,681) | (1,110,786) | (125,690) | (8,635) | |||
| Other undisclosed equity, attributable to parent | (1) | (156,600) | |||||
| Total equity: | 84,723 | 201,618 | 301,713 | 248,569 | |||
| TOTAL LIABILITIES AND EQUITY: | 228,057 | 248,400 | 460,979 | 248,569 | |||
Income Statement (P&L) (USD)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Revenues | 2,340 | 47,800 | 15,967 | 44 | ||
| Other income | 8 | 1,286 | 44 | |||
| Cost of revenue | (1,232) | (22,614) | (7,579) | |||
| Gross profit: | 1,108 | 25,186 | 8,388 | 44 | ||
| Operating expenses | (118,003) | 1,010,291 | (126,655) | (6,368) | ||
| Other undisclosed operating loss | (2,020,582) | |||||
| Operating loss: | (116,895) | (985,105) | (118,267) | (6,324) | ||
| Nonoperating income (Other Nonoperating income) | 8 | |||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (44) | |||||
| Loss from continuing operations: | (116,895) | (985,097) | (118,267) | (6,368) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (6,368) | |
| Other undisclosed net income | 1,970,194 | 44 | ||||
| Net income (loss): | (116,895) | 985,097 | (118,267) | (6,324) | ||
| Other undisclosed net income (loss) attributable to parent | (1,970,194) | 1,286 | ||||
| Net loss available to common stockholders, diluted: | (116,895) | (985,097) | (116,981) | (6,324) | ||
Comprehensive Income (USD)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | (116,895) | 985,097 | (118,267) | (6,324) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (116,895) | 985,097 | (118,267) | (6,324) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.